These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 36726813)

  • 21. Updated guidelines for immune thrombocytopenic purpura: Expanded management options.
    DeSouza S; Angelini D
    Cleve Clin J Med; 2021 Dec; 88(12):664-668. PubMed ID: 34857604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current Understanding of Immune Thrombocytopenia: A Review of Pathogenesis and Treatment Options.
    Mititelu A; Onisâi MC; Roșca A; Vlădăreanu AM
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Epidemiology and pharmacoepidemiology of immune thrombocytopenia].
    Moulis G; Lapeyre-Mestre M; Adoue D; Sailler L
    Rev Med Interne; 2017 Jul; 38(7):444-449. PubMed ID: 28131440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Thrombocytopenia (ITP): Current Limitations in Patient Management.
    Terrell DR; Neunert CE; Cooper N; Heitink-Pollé KM; Kruse C; Imbach P; Kühne T; Ghanima W
    Medicina (Kaunas); 2020 Nov; 56(12):. PubMed ID: 33266286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.
    Vianelli N; Auteri G; Buccisano F; Carrai V; Baldacci E; Clissa C; Bartoletti D; Giuffrida G; Magro D; Rivolti E; Esposito D; Podda GM; Palandri F
    Ann Hematol; 2022 May; 101(5):963-978. PubMed ID: 35201417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management.
    Beltrami-Moreira M; Sharma A; Bussel JB
    Expert Rev Hematol; 2024 Sep; 17(9):595-607. PubMed ID: 39105265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama.
    Watts RG
    Clin Pediatr (Phila); 2004 Oct; 43(8):691-702. PubMed ID: 15494875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controversies in the treatment of immune thrombocytopenia.
    Cuker A; Cines DB; Neunert CE
    Curr Opin Hematol; 2016 Sep; 23(5):479-85. PubMed ID: 27380558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiology, pathophysiology, and initial management of chronic immune thrombocytopenic purpura.
    Pruemer J
    Am J Health Syst Pharm; 2009 Jan; 66(2 Suppl 2):S4-10. PubMed ID: 19139489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice.
    Depré F; Aboud N; Mayer B; Salama A
    PLoS One; 2018; 13(6):e0198184. PubMed ID: 29856800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How we treat primary immune thrombocytopenia in adults.
    Liu XG; Hou Y; Hou M
    J Hematol Oncol; 2023 Jan; 16(1):4. PubMed ID: 36658588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Secondary ITP in adults].
    Michel M; Lega JC; Terriou L
    Rev Med Interne; 2021 Jan; 42(1):50-57. PubMed ID: 33139079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoimmune thrombocytopenia: Current treatment options in adults with a focus on novel drugs.
    Witkowski M; Witkowska M; Robak T
    Eur J Haematol; 2019 Dec; 103(6):531-541. PubMed ID: 31449692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of immune thrombocytopenic purpura in children: potential role of novel agents.
    Bredlau AL; Semple JW; Segel GB
    Paediatr Drugs; 2011 Aug; 13(4):213-23. PubMed ID: 21692546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?
    Lv Y; Shi H; Liu H; Zhou L
    Front Immunol; 2022; 13():953716. PubMed ID: 36003388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors and predictors of treatment responses and complications in immune thrombocytopenia.
    Ong SY; Tan CW; Ramya V; Malik AA; Lee XH; Hwang JCC; Yang Y; Ng HJ; Lee LH
    Ann Hematol; 2021 Mar; 100(3):645-651. PubMed ID: 33515047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is splenectomy a good strategy for refractory immune thrombocytopenia in adults?
    Godeau B
    Br J Haematol; 2023 Oct; 203(1):86-95. PubMed ID: 37735555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of immune thrombocytopenic purpura in children : current concepts.
    Shad AT; Gonzalez CE; Sandler SG
    Paediatr Drugs; 2005; 7(5):325-36. PubMed ID: 16220997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recommendations for the management of acute immune thrombocytopenia in children. A Consensus Conference from the Italian Association of Pediatric Hematology and Oncology.
    Russo G; Parodi E; Farruggia P; Notarangelo LD; Perrotta S; Casale M; Cesaro S; Del Borrello G; Del Vecchio GC; Giona F; Gorio C; Ladogana S; Lassandro G; Marzollo A; Maslak K; Miano M; Nardi M; Palumbo G; Rossi F; Spinelli M; Tolva A; Saracco P; Ramenghi U; Giordano P
    Blood Transfus; 2024 May; 22(3):253-265. PubMed ID: 37677093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of immune thrombocytopenia in women: current standards and special considerations.
    Rodeghiero F; Marranconi E
    Expert Rev Hematol; 2020 Feb; 13(2):175-185. PubMed ID: 31903814
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.